Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3487 | Umbilical cord derived mesenchymal stem cells Wiki | 0.71 |
drug2448 | Placebo Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D018352 | Coronavirus Infections NIH | 0.05 |
D007239 | Infection NIH | 0.03 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
Description: DLT will be assessed by DAIDS v2.1. The measurements include clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs
Measure: Dose-limiting toxicity(DLT) Time: 7 daysDescription: MTD will be assessed by DAIDS v2.1. The measurements include clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs.
Measure: Maximal Tolerable Dose(MTD) Time: 12 weeksDescription: Area under the curve from the time of dosing to the last measurable concentration time t (AUC0-t)
Measure: AUC0-t Time: 12 weeksDescription: Area Under the Concentration Time Curve (AUC) From Time Zero to Infinity (AUC 0-∞)
Measure: AUC0-∞ Time: 12 weeksDescription: Elimination Phase Half-life(t1/2)
Measure: t1/2 Time: 12 weeksDescription: Time to the Maximum Concentration(Tmax)
Measure: Tmax Time: 12 weeksDescription: Positive rate of anti-SCT A01 antibody
Measure: Anti-drug antibody(ADA) Time: 12 weeksDescription: Adverse events as assessed by DAIDS v2.1, including clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs
Measure: Adverse events Time: 12 weeksThe study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III trial, and will be conducted in approximately 40 sites globally. The study is comprised of two parts: dose selection (Phase II) and pivotal treatment effect (Phase III).
Description: As measured by RT-qPCR
Measure: The virologic efficacy of SCTA01 (Phase II) Time: Day 8Description: As assessed by time to clinical improvement (TTCI)
Measure: The clinical efficacy of SCTA01 (Phase III) Time: Day 29Description: TTCI
Measure: Clinical efficacy of SCTA01(Phase II) Time: Day 29Description: Cumulative incidence of serious adverse events in both Phase II and III
Measure: Cumulative incidence of SAEs(Phase II, III) Time: 3 MonthsDescription: Change from baseline in viral shedding as measured by RT-qPCR in in NP swab samples
Measure: Change from baseline in viral shedding as measured by RT-qPCR(Phase III) Time: Day 85Description: AUC0-t through Day 85
Measure: area under the curve (AUC0-t)(Phase II) Time: Day 85Description: AUC0-∞ through Day 85
Measure: AUC0-∞(Phase II) Time: Day 85Description: t1/2 through Day 85
Measure: Half-life time (t1/2)(Phase II) Time: Day 85Description: Cmax through Day 85
Measure: Maximum concentration (Cmax)(Phase II) Time: Day 85Description: Tmax through Day 85
Measure: Peak time (Tmax)(Phase II) Time: Day 85Description: CL through Day 85
Measure: Clearance (CL)(Phase II) Time: Day 85Description: Vd through Day 85
Measure: Apparent volume of distribution (Vd)(Phase II) Time: Day 85Description: λz through Day 85
Measure: Elimination rate constant (λz)(Phase II) Time: Day 85Description: ADA against SCTA01 at baseline and Day 29
Measure: Immunogenicity as measured by anti-drug antibodies (ADA) (Phase II, III) Time: Day 29Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports